Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

19.0%

11 terminated/withdrawn out of 58 trials

Success Rate

71.1%

-15.5% vs industry average

Late-Stage Pipeline

16%

9 trials in Phase 3/4

Results Transparency

81%

22 of 27 completed trials have results

Key Signals

3 recruiting22 with results8 terminated

Enrollment Performance

Analytics

Phase 1
24(42.9%)
Phase 2
23(41.1%)
Phase 3
8(14.3%)
Phase 4
1(1.8%)
56Total
Phase 1(24)
Phase 2(23)
Phase 3(8)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (58)

Showing 20 of 58 trials
NCT03601923Phase 2Completed

Niraparib in Patients With Pancreatic Cancer

Role: collaborator

NCT02655016Phase 3Active Not Recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Role: lead

NCT03830918Phase 1Active Not Recruiting

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Role: collaborator

NCT04068753Phase 2Active Not Recruiting

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Role: collaborator

NCT04774419Phase 2Recruiting

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Role: collaborator

NCT04165772Phase 2Recruiting

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Role: collaborator

NCT03368729Phase 1Active Not Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Role: collaborator

NCT02715284Phase 1Active Not Recruiting

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Role: lead

NCT04221503Phase 2Active Not Recruiting

Niraparib/TTFields in GBM

Role: collaborator

NCT03955978Phase 1Active Not Recruiting

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Role: collaborator

NCT03602859Phase 3Active Not Recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Role: lead

NCT03651206Phase 2Recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Role: collaborator

NCT06964165Phase 2Terminated

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Role: lead

NCT03307785Phase 1Completed

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Role: lead

NCT02817633Phase 1Active Not Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Role: lead

NCT04139902Phase 2Active Not Recruiting

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Role: collaborator

NCT03945721Phase 1Active Not Recruiting

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

Role: collaborator

NCT03981796Phase 3Active Not Recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Role: lead

NCT04080284Phase 2Completed

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Role: collaborator

NCT04409002Phase 2Completed

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Role: collaborator